MedTrace Logo

Gram-negative Bacilli and MRSA Screening in ICU in China

NCT04310722 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-03-20

No results posted yet for this study

Summary

Carbapenem-resistant Gram-negative bacilli \[Carbapenem-resistant Acinetobacter baumannii (CRAB), Carbapenem-resistant Klebsiella pneumoniae (CRKP), and Carbapenem-resistant Pseudomonas aeruginosa (CRPsA) \] and methicillin-resistant Staphylococcus aureus (MRSA) is prevalent around the world, and the isolation rate and resistance rate has increasing in China. The limited treatment and high mortality rate of these pathogens infections has resulted in difficulty in clinical anti-infection treatment, so it is urgent to illustrate the transmission mechanism, resistance mechanism and horizontal transfer mechanism of resistance genes in intensive care unit (ICU). Furthermore, this study was aimed to investigate the epidemiology and risk factors, outcomes and the rationality of the current therapy for these pathogens infections in China.

Conditions

  • Infections, Bacterial

Interventions

OTHER

None intervention. This is an observational study.

None intervention. This is an observational study.

Sponsors & Collaborators

  • University of Birmingham

    collaborator OTHER

  • Sir Run Run Shaw Hospital

    lead OTHER

Principal Investigators

  • Yun-song Yu, Dr. · Zhejiang University

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-06
Primary Completion
2020-10-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04310722 on ClinicalTrials.gov